Literature DB >> 8260359

cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo.

M Toi1, A L Harris, R Bicknell.   

Abstract

A tamoxifen resistant cell line (clone 9) has been isolated from the tamoxifen sensitive, hormone responsive MCF-7 breast carcinoma cell line after transfection with mixed cDNA libraries, followed by tamoxifen selection in the presence of oestrogens. Transfection was confirmed by Southern analysis with vector probes. Clone 9 in several-fold more resistant to tamoxifen and other anti-oestrogens than wild type cells when cultured either as a monolayer or as colonies in soft agar but retains oestrogen receptors. Clone 9 was less responsive to 17-beta-oestradiol than were wild type MCF-7. In addition to showing in vitro tamoxifen resistance, clone 9 was also tamoxifen resistant in vivo when xenografted into the nude mouse. Culture medium conditioned by clone 9 cells stimulated quiescent cells of the same clone as well as wild type cells, whereas medium conditioned by wild type MCF-7 was inhibitory to both, suggesting that clone 9 may be secreting an autocrine growth factor. Clone 9 provides a novel model for further investigation of the mechanism of anti-oestrogen resistance that occurs without loss of oestrogen receptors. Preliminary results suggest that an autocrine growth stimulatory mechanism may be one pathway of such resistance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260359      PMCID: PMC1968663          DOI: 10.1038/bjc.1993.486

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

Review 1.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

2.  Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.

Authors:  S Nicholson; J R Sainsbury; P Halcrow; P Chambers; J R Farndon; A L Harris
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

3.  Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

Authors:  E A Lien; E Solheim; O A Lea; S Lundgren; S Kvinnsland; P M Ueland
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

4.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw
Journal:  Mol Endocrinol       Date:  1989-04

6.  Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas.

Authors:  S Sukumar; W P Carney; M Barbacid
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

7.  Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.

Authors:  A L Harris; B M Cantwell; J Carmichael; P Dawes; A Robinson; J Farndon; R Wilson
Journal:  Eur J Cancer Clin Oncol       Date:  1989-07

Review 8.  Towards a molecular basis for tamoxifen resistance in breast cancer.

Authors:  S R Johnston; M Dowsett; I E Smith
Journal:  Ann Oncol       Date:  1992-07       Impact factor: 32.976

9.  Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors.

Authors:  K Smith; J A Fennelly; D E Neal; R R Hall; A L Harris
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

10.  Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

Authors:  S Nicholson; P Halcrow; J R Sainsbury; B Angus; P Chambers; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

View more
  3 in total

Review 1.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Thymidine phosphorylase is angiogenic and promotes tumor growth.

Authors:  A Moghaddam; H T Zhang; T P Fan; D E Hu; V C Lees; H Turley; S B Fox; K C Gatter; A L Harris; R Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

3.  Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line.

Authors:  J P Parisot; X F Hu; M DeLuise; J R Zalcberg
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.